ShanXi C&Y Pharmaceutical Group Co., Ltd. reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported sales was CNY 571.94 million compared to CNY 633.85 million a year ago. Revenue was CNY 571.94 million compared to CNY 633.85 million a year ago.

Net loss was CNY 13.69 million compared to CNY 25.37 million a year ago. Basic loss per share from continuing operations was CNY 0.0567 compared to CNY 0.1077 a year ago. Diluted loss per share from continuing operations was CNY 0.0567 compared to CNY 0.1077 a year ago.